跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Irixarri-100 - Philippines FDA Drug Approval Details
Approvals
/
Philippines FDA
/
Irixarri-100
Approved
STANDARD
Irixarri-100
ADMAC Lifesciences
🇵🇭 Food and Drug Administration - Philippines
Approval Date
Jul 14, 2025
Approval ID
c51178b8345b11bd
Company
ADMAC Lifesciences
Type
Standard
Approval Details
Approval Id
c51178b8345b11bd
Drug Approval Philippines Name
Irixarri-100
Product Name
Irixarri-100
Registration Number
DRP-13063
Brand Name
Irixarri-100
Generic Name
Irinotecan Hydrochloride (as trihydrate)
Dosage Form
Concentrate Solution For I.V Infusion
Dosage Strength
20mg/mL (100 mg/5 mL)
Manufacturer
ADMAC Lifesciences
Importer
Ambica International Corporation
Distributor
Ambica International Corporation
Issuance Date
24 November 2022
Expiry Date
24 November 2027
Classification
Prescription Drug (RX)
Active Ingredients
Approved
Quick Info
Agency
Philippines FDA
Country
🇵🇭
Approval Date
Jul 14, 2025
Approval ID
c51178b8345b11bd
Type
Standard
Back to Philippines FDA Approvals